Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has taken a significant step in protecting the brand identity of its lead product candidate. The company announced that it received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) on September 2, for commercial brand name trademarks associated with its abuse-deterrent fentanyl transdermal system. The trademarks are slated to appear in the USPTO Trademark Official Gazette, initiating a 30-day opposition period. If no objections are filed, the USPTO is expected to issue a Notice of Allowance, moving the trademarks closer to registration.
The fentanyl system incorporates Nutriband's AVERSA™ abuse-deterrent transdermal technology. This patch is designed to deter abuse and misuse while reducing the risk of accidental exposure to fentanyl, a potent opioid. The company has highlighted the product's potential peak annual U.S. sales of $80 million to $200 million, underscoring the commercial significance of protecting its trademarks. Additionally, the AVERSA™ technology itself is already protected by patents issued in 46 countries, providing a robust intellectual property portfolio.
This development is crucial for Nutriband as it prepares for potential commercialization. Securing trademark protection helps safeguard the brand and can prevent confusion in the marketplace. For the pharmaceutical industry, strong trademark and patent protection are vital to recouping research and development investments and ensuring market exclusivity. The abuse-deterrent aspect of the product also addresses a growing public health concern regarding opioid misuse, which could position the company favorably with regulators and healthcare providers.
Nutriband's focus on transdermal drug delivery is part of a broader trend in pharmaceuticals to develop alternative administration methods that improve patient compliance and safety. The AVERSA™ technology is designed to be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This versatility could expand the company's pipeline beyond fentanyl, potentially impacting multiple therapeutic areas.
Investors and industry observers will be watching the 30-day opposition period closely. A successful outcome would clear the path for trademark registration, reinforcing Nutriband's intellectual property position. The company's proactive approach to intellectual property protection is a positive signal for stakeholders, as it mitigates risks associated with brand infringement and supports a stronger market entry strategy.
For more information on Nutriband and its news, visit the company's newsroom at https://ibn.fm/NTRB. To view the full press release, visit https://ibn.fm/p1wVE.
